Padsevonil ( DrugBank: Padsevonil )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 149 | Hemiconvulsion hemiplegia epilepsy syndrome | 1 |
149. Hemiconvulsion hemiplegia epilepsy syndrome
Clinical trials : 25 / Drugs : 40 - (DrugBank : 14) / Drug target genes : 17 - Drug target pathways : 20
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-JapicCTI-194958 | 01/10/2019 | 18/09/2019 | A pharmacokinetic, safety, and tolerability study of padsevonil in CYP2C19 genotyped healthy male Japanese study participants. | An Open-Label, Parallel Group, Single-Center Study to Investigate the Pharmacokinetic, Safety, and Tolerability Profiles of Padsevonil in CYP2C19 Genotyped Healthy Male Japanese Study Participants | Epilepsy and epilepsy syndrome | Intervention name : padsevonil INN of the intervention : padsevonil Dosage And administration of the intervention : Oral administration Control intervention name : - INN of the control intervention : - Dosage And administration of the control intervention : - | UCB Japan Co., Ltd. | NULL | complete | 20 | 55 | Male | 39 | Phase 1 | Japan |